Načítá se...
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...
Uloženo v:
| Vydáno v: | Curr Rheumatol Rep |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8065312/ https://ncbi.nlm.nih.gov/pubmed/33893890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-021-00998-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|